AR085059A1 - Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarla - Google Patents
Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarlaInfo
- Publication number
- AR085059A1 AR085059A1 ARP120100388A ARP120100388A AR085059A1 AR 085059 A1 AR085059 A1 AR 085059A1 AR P120100388 A ARP120100388 A AR P120100388A AR P120100388 A ARP120100388 A AR P120100388A AR 085059 A1 AR085059 A1 AR 085059A1
- Authority
- AR
- Argentina
- Prior art keywords
- dissolved
- composition
- active pharmaceutical
- dose inhaler
- cosolvent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000005260 corrosion Methods 0.000 title abstract 3
- 230000007797 corrosion Effects 0.000 title abstract 3
- 238000005259 measurement Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 4
- 239000006184 cosolvent Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000004820 halides Chemical class 0.000 abstract 2
- 239000003380 propellant Substances 0.000 abstract 2
- 239000000375 suspending agent Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical group OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical group O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 abstract 1
- 229960002630 ipratropium bromide monohydrate Drugs 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Inhaladores farmacéuticos presurizados de dosis medida (IDM), que contienen al menos un haluro disuelto, una sustancia farmacéutica suspendida, una sustancia farmacéutica disuelta y un cosolvente, estabilizados químicamente y también contra la corrosión metálica mediante la adición de un ácido, un agente suspensor insaturado y agua.Reivindicación 1: Una composición resistente a la corrosión y farmacéuticamente estable para inhalador presurizado de dosis medida, caracterizada porque comprende: al menos un ingrediente farmacéutico activo suspendido; al menos un ingrediente farmacéutico activo disuelto; un haluro disuelto; al menos un cosolvente; al menos un propulsor; entre 0,1 y 10% p/p de agua; entre 0,0001 y 0,01% p/p de un ácido orgánico; y entre 0,01 a 0,3% p/p un agente suspensor insaturado. Reivindicación 9: La composición de la reivindicación 1, caracterizada porque dicho ingrediente farmacéutico activo suspendido es sulfato de salbutamol y el ingrediente farmacéutico activo disuelto es bromuro de ipratropio monohidrato. Reivindicación 10: La composición de la reivindicación 1, caracterizada porque dicho cosolvente es etanol o isopropanol. Reivindicación 13: La composición de la reivindicación 1, caracterizada porque dicho propulsor es una mezcla de dicho hidrocarburo y dicho fluorohidrocarburo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/024,414 US20120204871A1 (en) | 2011-02-10 | 2011-02-10 | Stable, non-corrosive formulations for pressurized metered dose inhalers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085059A1 true AR085059A1 (es) | 2013-08-07 |
Family
ID=45607025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100388A AR085059A1 (es) | 2011-02-10 | 2012-02-07 | Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarla |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20120204871A1 (es) |
| EP (1) | EP2486914A3 (es) |
| AR (1) | AR085059A1 (es) |
| BR (1) | BR102012002923A2 (es) |
| CL (1) | CL2012000327A1 (es) |
| DE (1) | DE102012102218A1 (es) |
| MX (2) | MX353975B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10610512B2 (en) | 2014-06-26 | 2020-04-07 | Island Breeze Systems Ca, Llc | MDI related products and methods of use |
| EP3174522A1 (en) | 2014-07-29 | 2017-06-07 | 3M Innovative Properties Company | Method of preparing a pharmaceutical composition |
| WO2016164508A1 (en) * | 2015-04-10 | 2016-10-13 | 3M Innovative Properties Company | Formulation and aerosol canisters, inhalers, and the like containing the formulation |
| WO2016187156A1 (en) * | 2015-05-21 | 2016-11-24 | Island Breeze Systems Ca, Llc | Propellant based metered dose inhaler and food applicators and applicators |
| EA202092976A1 (ru) * | 2018-06-04 | 2021-03-16 | Люпин Инк. | Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением |
| IL305534A (en) * | 2021-03-23 | 2023-10-01 | 1232176 B C Ltd | device for the treatment of anaphylaxis |
| WO2025128797A1 (en) | 2023-12-13 | 2025-06-19 | Blue Evolution, Inc | Ecofriendly, biodegradable biological polysaccharide composition for packaging materials |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| DE4132176C2 (de) | 1991-09-27 | 1997-03-13 | Ig Spruehtechnik Gmbh | Dosieraerosole mit Isobutan als Treibmittel |
| ATE171865T1 (de) | 1991-12-12 | 1998-10-15 | Glaxo Group Ltd | Arzneimittel |
| RO117414B1 (ro) | 1992-12-09 | 2002-03-29 | Jager Paul D Waterbury | Compozitie farmaceutica de aerosol in solutie |
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| US6739333B1 (en) | 1999-05-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Stainless steel canister for propellant-driven metering aerosols |
| US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| SE0200312D0 (sv) | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| ME00420B (me) * | 2003-03-20 | 2011-12-20 | Boehringer Ingelheim Pharmaceuticals Inc | Formulacija, za inhalator u kojem se odmjerava doza, u kojoj se kao propelenti koriste hidro-fluoro-alkani |
| AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| UA99466C2 (en) * | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
-
2011
- 2011-02-10 US US13/024,414 patent/US20120204871A1/en not_active Abandoned
- 2011-03-19 US US13/052,054 patent/US20120207685A1/en not_active Abandoned
-
2012
- 2012-02-07 AR ARP120100388A patent/AR085059A1/es unknown
- 2012-02-08 MX MX2012001693A patent/MX353975B/es active IP Right Grant
- 2012-02-08 CL CL2012000327A patent/CL2012000327A1/es unknown
- 2012-02-09 EP EP12154637A patent/EP2486914A3/en not_active Withdrawn
- 2012-02-09 BR BRBR102012002923-5A patent/BR102012002923A2/pt not_active IP Right Cessation
- 2012-03-16 MX MX2012003303A patent/MX2012003303A/es active IP Right Grant
- 2012-03-16 DE DE102012102218A patent/DE102012102218A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CL2012000327A1 (es) | 2014-07-11 |
| US20120204871A1 (en) | 2012-08-16 |
| MX2012003303A (es) | 2012-09-18 |
| DE102012102218A1 (de) | 2013-06-20 |
| MX353975B (es) | 2018-02-07 |
| US20120207685A1 (en) | 2012-08-16 |
| EP2486914A2 (en) | 2012-08-15 |
| BR102012002923A2 (pt) | 2013-07-23 |
| EP2486914A3 (en) | 2012-09-05 |
| MX2012001693A (es) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085059A1 (es) | Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarla | |
| AR130238A2 (es) | Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de un envase de aerosol asociado | |
| AR130239A2 (es) | Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de una lata de aerosol asociada | |
| AR081364A1 (es) | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion | |
| PE20121396A1 (es) | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| BR112018011777A2 (pt) | composições de fenfluramina e métodos para o preparo das mesmas | |
| CO6612278A2 (es) | Composición acuosa antitranspirante/desodorante | |
| BR112014010291A2 (pt) | composições de lipossoma combinacionais para terapia de câncer | |
| NI201300054A (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas | |
| BR112014009031A2 (pt) | formulações de etanercept estabilizadas com íons de metais | |
| UY30139A1 (es) | Formulacion farmaceuica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| AR089302A1 (es) | Un medicamento inhalable | |
| CL2012001668A1 (es) | Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros. | |
| CL2013002810A1 (es) | Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. | |
| MX2021003599A (es) | Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion. | |
| BR112012021657A2 (pt) | composto, agentes farmacêutico, agonístico de casr, e agente para conferir kokumi, e, temperos | |
| CO6351721A2 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
| AR040450A1 (es) | Formulacion superfina de salmeterol | |
| BR112014005538A2 (pt) | composições aquosas compreendendo arbecacina | |
| AR087787A1 (es) | Compuesto de benzotiazolona | |
| BR112014024052A8 (pt) | Derivado de ácido nipecótico, produto farmacêutico, inibidor de hidrolase de epóxido solúvel, e, agente terapêutico ou profilático | |
| PE20070353A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
| UY26991A1 (es) | Formulación en solución inhalable con una sal de tiotropio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |